Lundbeck sees $250 mln Xenazine sales in 2012-15

COPENHAGEN, July 7 (Reuters) - The head of Danish pharmaceuticals group H. Lundbeck A/S (LUN.CO) said on Tuesday that he expected sales of the drug Xenazine to reach $250 million in 2012-2015.

Chief Executive Ulf Wiinberg also told Reuters that Lundbeck would have exclusive rights to Xenazine, a drug for a symptom associated with Huntington's disease, to 2016.

The remarks came after Lundbeck said it agreed to acquire UK-based drugs firm LifeHealth, the holder of the rights to the drug, for $147 million.

(Reporting by Peter Levring.